摘要
目的:评价吸入用倍氯米松/福莫特罗气雾剂(启尔畅)临床应用情况,为临床用药提供借鉴。方法:查阅国内外相关文献,对启尔畅临床使用的适应症、有效性、安全性、经济学等方面进行评价。结果与结论:作为哮喘控制用药,启尔畅的疗效与其他吸入用药相当,且安全性更高,用药费用经济合理,是临床医师安全放心的处方选择。
Objective: To do the evaluation of clinical application of Beclometasone and Formoterol Inhalation Aerosol (FOSTER), and provide the reference for clinical practice. Method: We searched the relevant literatures from domestic and abroad resources, and reviewed the indications, treatment efficacy, safety and cost-benefit of FOSTER. Result and Conclusion: FOSTER as one kind of controllers for asthma treatment has similar efficacy with other controllers. Due to less side effect and cheaper cost, FOSTER could be a better choice for prescription.
作者
贡联兵
GONG Lian-bing(Pharmacy department of the 305 hospital of people's liberation army, Beijing 100017, China)
出处
《药品评价》
CAS
2016年第20期38-41,44,共5页
Drug Evaluation